Evidence map›Paper›PMID 42712886›Full record

ArticleBleeding, thrombosis and vascular biology2026

Trypsin is as procoagulant as factor XIIa.

Stephanie A Smith, James H Morrissey

Abstract read
In one paragraph

Article in Bleeding, thrombosis and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stephanie A SmithDepartment of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan, United States.
James H MorrisseyDepartment of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan, United States.

Funding

Mechanisms in Blood ClottingR35HL171334 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI James H. Morrissey · 2024 to 2026
$2.9M
NHLBI NIH HHS R35 HL171334
6 · The paper itself

Abstract

Background: To help shed light on the roles of the contact pathway of blood clotting, we quantified the relative procoagulant activities of each of the serine proteases of the clotting cascade. Methods: We added varying concentrations of the activated forms of different clotting proteases to normal human plasma and recorded the time to clot formation. We also compared these clotting activities to that of the nonspecific serine protease, trypsin. Results: The activated proteases of the final common pathway of blood clotting exhibited relatively strong clotting activity and achieved 100-second clotting times at pM to very low nM concentrations. In contrast, factor XIIa and plasma kallikrein exhibited weak clotting activity such that it required nearly 100 nM factor XIIa to achieve a 100-second clotting time, and for plasma kallikrein this was not achieved even with 100 nM enzyme. Trypsin was slightly more procoagulant than factor XIIa. Conclusions: The enzymes that trigger the contact pathway of blood clotting have remarkably weak procoagulant activity. The implications for the roles of factor XII and trypsin in thrombotic disorders and pancreatitis are discussed.

Indexed as

blood clottingcontact pathwaypancreatitisthrombosistrypsin

Identifiers

PMID42712886
PMCPMC13552055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.